Notice of Interim Results

RNS Number : 9014V
Advanced Medical Solutions Grp PLC
27 July 2018

27 July 2018


Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)


Notice of Interim Results


Winsford, UK, 27 July 2018: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, will announce its interim results for the six months ended 30 June 2018 on Wednesday 12 September 2018.


A briefing for analysts will be held at 10.30am BST on the day of results in The Dome Room at 1 Cornhill, London EC3V 3ND. Please contact Consilium Strategic Communications for further details.


– End –


For further information, please visit or contact:


Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508


Chris Meredith, Chief Executive Officer

Mary Tavener,  Chief Financial Officer



Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700


Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser



Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970


Daniel Adams / Gary Clarence / Patrick Robb






About Advanced Medical Solutions Group plc – see


AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.


AMS‘s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 600 employees.  For more information, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit